Document is current
Any future updates will be listed below
-
Authors
Wander, S. A.
Weipert, C. M.
Cabel, L.
Liao, J.
Zhang, N.
Safonov, A.
Bardia, A.
Razavi, P.
-
Funding
Funding for this research was provided by:
NCI Cancer Center Support Grant CCSG (P30CA008748)
NCI Cancer Center Support Grant CCSG (P30CA008748)
NCI Cancer Center Support Grant CCSG (P30CA008748)
Susan G. Komen Foundation (NA)
- License Information
-
More Information
Article History
Received: 17 February 2026
Accepted: 25 May 2026
First Online: 12 June 2026
Competing interests
: Wander SA: consulting/advisory board for Foundation Medicine, Veracyte, Pfizer, AstraZeneca, Biovica, Puma Biotechnology, Eli Lilly; speaking/education for 2ndMD, Eli Lilly, Guardant Health; institutional research support from Genentech, Eli Lilly, Pfizer, Nuvation Bio, Regor Therapeutics, Sermonix. Weipert CM: Employee and stockholder of Guardant Health, Inc.Cabel L: None.Liao J: Employee and stockholder of Guardant Health, Inc.Zhang N: Employee and stockholder of Guardant Health, Inc.Safonov A: None.Bardia A: Consultant/Advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/AstraZeneca, Phillips, Eli Lilly, Foundation Medicine. Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/AstraZeneca, Eli Lilly, Natera.Razavi P: received institutional grant/funding: NIH, Komen, Breast Cancer Alliance, BCRF, Grail, Novartis, AstraZeneca, Roche, Invitae, Biothernostics, Tempus, Inivata, Guardant Health, Personalis, Myriad Genetics, SAGA Diagnostics, SOPHiA Genetics, Natera/Foresight, Haystack, Consulting/Ad board/Advisor for Novartis, AstraZeneca, Pfizer, Lilly/Loxo, Prelude Therapeutics, NeoGenomics, Tempus, SAGA Diagnostics, Pathos, SOPHiA Genetics Guardant, Myriad, Menarini, BioNTech.
